Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.78
-0.0400-0.25%
Volume:3.43M
Turnover:54.16M
Market Cap:3.18B
PE:-19.09
High:15.96
Open:15.93
Low:15.65
Close:15.82
52wk High:15.97
52wk Low:9.84
Shares:201.40M
Float Shares:195.63M
Volume Ratio:0.88
T/O Rate:1.75%
Dividend:1
Dividend Rate:6.34%
EPS(TTM):-0.8265
EPS(LYR):-1.4300
ROE:-4.86%
ROA:2.75%
PB:1.03
PE(LYR):-11.03

Loading ...

Park Hotels forecasts FY 2026 adjusted EBITDA of $587 million-$617 million

Reuters
·
Jun 01

Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026

GlobeNewswire
·
Jun 01

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

GlobeNewswire
·
May 29

Park Hotels & Resorts (PK) Is Up 9.1% After Strong Q1 RevPAR Beat And Non-Core Asset Sale

Simply Wall St.
·
May 28

Park Hotels & Resorts Is Maintained at Hold by Truist Securities

Dow Jones
·
May 27

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

GlobeNewswire
·
May 26

Truist Raises Price Target on Park Hotels & Resorts to $13 From $12, Keeps Hold Rating

MT Newswires Live
·
May 26

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

GlobeNewswire
·
May 22

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

GlobeNewswire
·
May 22

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

GlobeNewswire
·
May 19

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

GlobeNewswire
·
May 15

Press Release: Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

Dow Jones
·
May 15

Galmed reports results from first-in-man PK study of Aramchol Meglumine

TIPRANKS
·
May 14

Press Release: Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
May 14

Park Hotels & Resorts Price Target Maintained With a $12.00/Share by Cantor Fitzgerald

Dow Jones
·
May 13

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
May 13

Park Hotels & Resorts Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
May 13

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

GlobeNewswire
·
May 12

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

GlobeNewswire
·
May 12

Press Release: Sionna Therapeutics Reports First Quarter 2026 Financial Results

Dow Jones
·
May 12